Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity

Bruton’s tyrosine kinase (BTK) is an attractive target for treating patients with B cell malignancies and autoimmune diseases. Many BTK inhibitors have been identified; however, like other kinase inhibitors, they lack diversity in their core structures. Therefore, it is important to secure a novel s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Hyewon, Lee, Eun, Kwon, Hye Ah, Seul, Lee, Jeon, Hui-Jeon, Yu, Ji Hoon, Ryu, Jae-Ha, Jeon, Raok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663272/
https://www.ncbi.nlm.nih.gov/pubmed/33113810
http://dx.doi.org/10.3390/ijms21217919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663272/
https://www.ncbi.nlm.nih.gov/pubmed/33113810
http://dx.doi.org/10.3390/ijms21217919

Ejemplares similares